Replies to post #237013 on Biotech Values

[DewDiligence]

BMY—Breyanzi shows phase-3 statsig-superior EFS compared to SoC (high-dose chemo followed by stem-cell transplant) in second-line, large B-cell lymphoma:

https://www.businesswire.com/news/home/20210610005259/en

Bryanzi’s existing label includes only the third-line setting (#msg-161552697).